Abstract
Protein glycation and oxidation contribute to the pathogenesis of neurodegenerative diseases. This study evaluated the antiglycative and antioxidative effects of donepezil, rivastigmine, galantamine, memantine, lamotrigine, sodium valproate, and carbamazepine using bovine serum albumin (BSA) as a model protein. Glycation was induced with fructose, ribose, or methylglyoxal (MGO), and oxidation with chloramine T (ChT). Concentrations of glycation products-Amadori products (APs), amyloid cross-β structure (βA), argpyrimidine (ARG), crossline (CRO), vesperlysine (VES), pentosidine (PEN), total AGEs and glycoxidation products-dityrosine (DT), kynurenine (KN), N-formylkynurenine (NFK) as well as oxidation biomarkers, total thiols (TTs), protein carbonyls (PCs), and advanced oxidation protein products (AOPPs), were determined via spectrophotometric and spectrofluorimetric methods. Molecular docking and a systematic literature review (PRISMA) complemented the experimental data. Lamotrigine showed the strongest antiglycative and antioxidative effects, surpassing aminoguanidine in reducing ARG, PEN, DT, and NFK levels. In contrast, donepezil markedly increased APs, βA, ARG, VES, DT, and PEN, suggesting proglycative and pro-oxidative activity. Docking revealed a high affinity of donepezil for RAGE (-7.2 kcal/mol), possibly explaining its impact on carbonyl stress. Overall, anti-dementia drugs showed weak to moderate antiglycative potential, with lamotrigine being the most effective.